Apogee Therapeutics, Inc. Announces Pricing of $350 Million Underwritten Public Offering

Group 1 - Apogee Therapeutics, Inc. has announced a public offering of 5,000,000 shares of common stock at a price of $70.00 per share, aiming for gross proceeds of approximately $350 million before expenses [1] - The offering is expected to close on March 26, 2026, pending customary closing conditions [1] - Underwriters have an option to purchase an additional 750,000 shares within 30 days at the public offering price [1] Group 2 - Jefferies, TD Cowen, Stifel, and Guggenheim Securities are acting as joint book-running managers for the offering, with Wedbush PacGrow and BTIG as lead managers [2] - An automatically effective shelf registration statement was filed with the SEC on August 12, 2024, and the offering is being made through a written prospectus [3] Group 3 - Apogee Therapeutics is focused on developing novel biologics for inflammatory and immunology markets, targeting conditions such as Atopic Dermatitis, asthma, Eosinophilic Esophagitis, and Chronic Obstructive Pulmonary Disease [5] - The company's lead program, Zumilokibart (APG777), is being developed for Atopic Dermatitis, which is a significant and under-penetrated market [5] - Apogee aims to achieve best-in-class efficacy and dosing through its antibody programs, which are designed to overcome limitations of existing therapies [5]